CPhI South East Asia opening Thailand edition in 2019

CPhI South East Asia opening Thailand edition in 2019
QSNCC in Bangkok

From 2019 onwards, CPhI South East Asia will alternate its annual location between the region’s two largest pharma economies – Indonesia and Thailand.

In 2019, CPhI South East Asia will take place at the Queen Sirikit National Convention Center (QSNCC) in Bangkok, Thailand before returning to Jakarta International Expo (JIExpo) in Indonesia in 2020.

CPhI South East Asia’s strategic move to Thailand will further strengthen the event’s appeal within the region. Organisers’ anticipate a significant growth in new visitors from more diverse locations with the new venue, catering to attendees that were previously unable to participate.

The event’s first visit to Thailand comes at a significant time for the country, as pharma sales are expected to grow by 8.4% in 2019, with multinational corporations increasingly looking to partner with local contract manufacturers in order to expedite and streamline market access.

According to data from BMI Research, by 2021 the pharmaceutical market is forecast to reach a value of $6.3 billion, experiencing a compound annual growth rate (CAGR) of 5.4% in local currency terms and 6.8% in US dollar terms.

Over the extended forecast period, medicine sales will experience a 10-year CAGR of 5.5% and 6.3% in local currency and US dollar terms respectively, reaching $8.4 billion by 2026.

“This is very much a natural progression for the CPhI South East Asia and the region, opening even greater opportunities to meet new partners and expand pharma sales. Collectively, these two countries account for over 50% of the region’s sales,” said Chris Kilbee, Group Director, Pharma at show organisers UBM.

“Our research shows there is large opportunity, in particular, for contract services and ingredients, and by annually switching location we will increase the depth and quality of regional partners available. Not to mention, we attract a wider perspective of visitors, all of which will ultimately accelerate ASEAN’s Pharmaceutical harmonisation and cross-border collaborations.”

In fact, according to PhRMA’s Special 301 submission for 2017, Thailand was once again designated as a ‘Priority Watch List Country’. Notably, only India and Indonesia share this status in the entire Asia Pacific region.

Mr Kilbee added: “The 2019 edition will open increased international opportunities for domestic manufacturers in Thailand that have not yet had the capacity or partners to expand regionally. Plus, with MNCs looking to capitalise on regulatory changes this year, we expect many new international attendees.”


Please enter your comment!
Please enter your name here